Carlyle Announces Sale of Thomas Scientific to Broad Sky Partners
New York, New York, January 27, 2022 – Global investment firm Carlyle (NASDAQ: CG) today announced that funds managed by Carlyle have sold Thomas Scientific, a leading distributor and sourcing partner to the life sciences industry, to Broad Sky Partners. Financial terms of the transaction were not disclosed.
Founded in 1900, Thomas Scientific provides a comprehensive offering of supplies, equipment, and supply chain solutions to the scientific community – supporting all laboratory research, biopharmaceutical, medical device, clinical diagnostics, cleanroom, and other related end markets. With a national network of eight distribution and service centers, supported by a highly technical commercial, customer service and strategic sourcing organization, Thomas Scientific has been a trusted partner to the scientific community for over 120 years.
Since acquiring Thomas Scientific in 2017, Carlyle successfully partnered with the management team to accelerate the company’s growth by broadening its product capabilities and distribution footprint through four complementary add-on acquisitions. Carlyle also saw the potential for value creation by helping Thomas Scientific expand into higher growth end markets including biopharma and molecular diagnostics. In addition to these growth initiatives, Thomas Scientific enhanced its focus from a pure-play distributor to a global strategic sourcing partner, allowing it to serve many new customers throughout the pandemic.
Vipul Amin, Managing Director, Carlyle said: “We are proud of our partnership with the world-class management team at Thomas Scientific to transform the business from a leading regional to a leading national player, with a comprehensive product offering, excellent customer service and reliable supply chain serving both small and large labs. Undoubtedly, Thomas is uniquely positioned to continue to expand its market presence.”
James Shillito, Principal, Carlyle added: “The future is bright for Thomas Scientific to build upon the foundational investments made in recent years. Carlyle is proud to have played a role in accelerating the company’s growth and setting the stage for the next 100 years of this storied brand.”
Charles Simmons, President & CEO, Thomas Scientific said: “These last four years have been transformational for our company and Carlyle’s resources and counsel have been instrumental in creating meaningful value and positioning Thomas Scientific to expand its capabilities to serve our customers.”
Jefferies LLC served as lead financial advisor, Baird served as financial advisor and Latham & Watkins LLP served as legal advisor to Thomas Scientific.
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $293 billion of assets under management as of September 30, 2021, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 1,800 people in 26 offices across five continents. Further information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.